Research Analysts Set Expectations for CNTX FY2025 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Equities researchers at William Blair lowered their FY2025 earnings estimates for shares of Context Therapeutics in a report issued on Thursday, November 6th. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of ($0.34) for the year, down from their previous forecast of ($0.32). The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. William Blair also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.10) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.48) EPS and FY2028 earnings at ($0.66) EPS.

Several other analysts have also recently commented on CNTX. HC Wainwright raised their target price on Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Cantor Fitzgerald started coverage on Context Therapeutics in a research note on Thursday, October 2nd. They issued an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Thursday, November 6th. Finally, Guggenheim started coverage on shares of Context Therapeutics in a research report on Thursday, September 18th. They issued a “buy” rating and a $5.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $5.40.

Context Therapeutics Trading Down 0.8%

Shares of NASDAQ CNTX opened at $1.19 on Monday. The stock has a 50 day simple moving average of $1.08 and a 200-day simple moving average of $0.86. The company has a market cap of $109.34 million, a PE ratio of -4.96 and a beta of 1.94. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.10.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01).

Institutional Investors Weigh In On Context Therapeutics

A hedge fund recently raised its stake in Context Therapeutics stock. Vanguard Group Inc. lifted its holdings in Context Therapeutics Inc. (NASDAQ:CNTX) by 4.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,495,031 shares of the company’s stock after purchasing an additional 134,449 shares during the period. Vanguard Group Inc. owned about 3.90% of Context Therapeutics worth $3,387,000 at the end of the most recent reporting period. 14.03% of the stock is owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.